134 related articles for article (PubMed ID: 20074932)
21. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Risch HA; Puopolo M; Yu H
Clin Cancer Res; 2006 Feb; 12(4):1208-14. PubMed ID: 16489075
[TBL] [Abstract][Full Text] [Related]
22. Evidence of molecular alterations in the tumour suppressor gene WWOX in benign and malignant bone related lesions of the jaws.
Diniz MG; Borges ER; Pimenta FJ; De Mesquita Netto AC; De Marco L; Gomez RS; Gomes CC
Oncol Rep; 2011 Feb; 25(2):499-502. PubMed ID: 21165567
[TBL] [Abstract][Full Text] [Related]
23. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
24. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.
Hata K; Dhar DK; Watanabe Y; Nakai H; Hoshiai H
Eur J Cancer; 2007 Jun; 43(9):1452-9. PubMed ID: 17442564
[TBL] [Abstract][Full Text] [Related]
25. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma.
Yang J; Cogdell D; Yang D; Hu L; Li H; Zheng H; Du X; Pang Y; Trent J; Chen K; Zhang W
Cancer Lett; 2010 May; 291(1):31-8. PubMed ID: 19896763
[TBL] [Abstract][Full Text] [Related]
26. A role for the WWOX gene in prostate cancer.
Qin HR; Iliopoulos D; Semba S; Fabbri M; Druck T; Volinia S; Croce CM; Morrison CD; Klein RD; Huebner K
Cancer Res; 2006 Jul; 66(13):6477-81. PubMed ID: 16818616
[TBL] [Abstract][Full Text] [Related]
27. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
28. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.
Anttila MA; Kosma VM; Hongxiu J; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
Br J Cancer; 1999 Apr; 79(11-12):1870-8. PubMed ID: 10206307
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
30. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
31. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
32. Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells.
Zhou YL; Li YC; Shou F; Liu CQ; Pu Y; Tang H
Chin Med J (Engl); 2010 Mar; 123(5):615-20. PubMed ID: 20367991
[TBL] [Abstract][Full Text] [Related]
33. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
34. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
35. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
[TBL] [Abstract][Full Text] [Related]
36. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
37. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
38. Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer.
Grimm C; Polterauer S; Zeillinger R; Tong D; Heinze G; Wolf A; Natter C; Reinthaller A; Hefler LA
Anticancer Res; 2010 Sep; 30(9):3487-91. PubMed ID: 20944127
[TBL] [Abstract][Full Text] [Related]
39. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
40. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
